BOSTON - 10/27/2018 — SOMERVILLE, MA — October 26, 2018— Andarix Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for cancer announced today that it will present the results of its latest clinical trial in lung cancer patients. The trial focused on the administration of Tozaride, the company's lead candidate in neuroendocrine lung cancer patients. The abstract is entitled “Targeted Clinical Study with 188 Re P2045 in lung cancer expressing SSTR and well differentiated Neuroendocrine tumours,” and will be presented at the SNMMI Northeast Regional Meeting 2018 in Newport, RI. October 26-28, 2018.
Tozaride is a novel, best-in-class cancer therapy based on a radio-labeled somatostatin peptide analogue. Early clinical studies of Tozaride demonstrated that it is well tolerated and may produce prolonged stable disease and improved overall survival in advanced lung cancer patients whose disease has continued to progress after failing other therapies. Tozaride targeted radiotherapy represents a new treatment paradigm which is expected to yield significant clinical benefit for both lung cancer (SCLC, NSCLC), and pancreatic cancer patients. Along with its companion diagnostic that helps identify patients most likely to respond – those with enough expression of the peptide’s target – Tozaride could provide another treatment option for patients who are not eligible for, or who have not responded to current therapies.
About Andarix Pharmaceuticals
Andarix Pharmaceuticals is at the forefront of personalized therapies for cancer, developing both the imaging agents that can identify appropriate patients, as well as the targeted therapies for these patients. The company’s products have progressed through early clinical development.The Andarix technology is based on a proprietary somatostatin peptide conjugate applicable to lung, pancreatic, neuroendocrine, and other cancers. Extensive research has demonstrated that somatostatin receptors are highly up-regulated on several solid tumors, particularly lung, neuroendocrine, and pancreatic tumors. To learn more about Andarix, please visit www.andarix.com.
Media Contacts:Company Name: Andarix Pharmaceuticals